

Published based on [MS Potential Treatment - This New Drug Reveals Unbelievable Potential](#)

MS Potential Treatment - This New Drug Reveals Unbelievable Potential

There may be excellent news for these folks whose daily lives are overshadowed by [multiple sclerosis](#). The race is finally on to develop a more practical treatment for the disease between main drug manufactures. Merck has been in the process of testing their newest treatment Cladribine as a possible MS treatment. Their research has proven that sufferers who have undergone a short collection of therapies with this new oral drug have a high rate of success in reaching decreased relapse rates when in comparison with most of the currently out there medications for [multiple sclerosis](#).

To emphasize the potential for Cladribine as a treatment for MS the manufacturer offered a report to the European Committee for Treatment and Research in Multiple Sclerosis Congress. The results they offered showed involved a research group consisting of sufferers who took one of 2 different doses or a placebo. The outcomes showed that forty three and 44 per cent of these taking the drug had been discovered to be symptom free for a interval of 2 full years. This was in comparison with solely 16 per cent of those who got the placebo.

Merck is currently working hard with the FDA to achieve approval at the same time as their rivals at Biogen and Novartis are creating mediations and looking for approval. The overall potential for Cladribine as an MS treatment is slightly overshadowed by a very slight threat of cancer in some patients. As this may be the first oral treatment out there for MS sufferers and as such might be a possible blockbuster for the manufacturer.

One of many largest benefits of this treatment is for these in the late stage of multiple sclerosis are far less prone to end up being disabled. It has also been proven that this new drug will help to reduce the danger of lesions developing. In line with many neurologists the potential for Cladribine as an MS treatment far outweighs any identified risks and in fact they're far more likely to prescribe this new drug for their sufferers in any part of the disease over the drugs being developed by both Novartis or Biogen.

Irrespective of which set of tests you take a look at the numbers coming back show the particular potential of Cladribine as a treatment for MS. Sufferers who have waited years for a truly efficient treatment are anxiously awaiting approval of this new treatment and are praying that the FDA does not drag their feet. That is the first new treatment to come along in many years to point out this kind of potential and anticipation is high in both the medical community and sufferers alike.

You can also find this article published on [MS Potential Treatment - This New Drug Reveals Unbelievable Potential](#), and on the tag pages [cure](#), [health](#), [medical](#), [natural remedy](#), [treatment](#).